Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity

Cardiovascular Research

Volumn 73, Issue 2, 2007, Pages 368-375

  Mundy, Alexa L ^a   Haas, Elvira ^a   Bhattacharya, Indranil ^a   Widmer, Corinne C ^a   Kretz, Martin ^a   Hofmann Lehmann, Regina ^b   Minotti, Roberta ^a   Barton, Matthias ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Artery; Atherosclerosis; Comparative; Glucose tolerance; Hydroxyl; ROS; Vascular disease; Vasoactive agents

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; HYDROXYL RADICAL; N(G) NITROARGININE METHYL ESTER; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; FAT INTAKE; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VASOCONSTRICTION; VASODILATATION;

ACETYLCHOLINE; ANGIOTENSIN II; ANIMALS; AORTA; BLOTTING, WESTERN; CHOLESTEROL; DIETARY FATS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HYDROXYL RADICAL; MALE; MICE; MICE, INBRED C57BL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OBESITY; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 33845574406     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.11.019     Document Type: Article

References (51)

1. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., and Koplan J.P. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282 (1999) 1519-1522
2. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
3. Barton M., and Furrer J. Cardiovascular consequences of the obesity pandemic: need for action. Expert Opin Investig Drugs 12 (2003) 1757-1759
4. Duprez D.A. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 24 (2006) 983-991
5. Dandona P., Aljada A., Chaudhuri A., and Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 2422-2429
6. Schulman I.H., Zhou M.S., and Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl 24 (2006) S45-S50
7. Schulman I.H., Zhou M.S., and Raij L. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Curr Hypertens Rep 7 (2005) 61-67
8. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol in press, doi:10.1152/ajpcell.00287.2006.
9. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
10. Touyz R.M., Tabet F., and Schiffrin E.L. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30 (2003) 860-866
11. Brasier A.R., Recinos III A., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22 (2002) 1257-1266
12. Cheng Z.J., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005) RA194-RA205
13. Itoh H., Mukoyama M., Pratt R.E., Gibbons G.H., and Dzau V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91 (1993) 2268-2274
14. Keidar S., Kaplan M., Hoffman A., and Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 115 (1995) 201-215
15. Mukai Y., Shimokawa H., Higashi M., Morikawa K., Matoba T., Hiroki J., et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 22 (2002) 1445-1450
16. Barton M., Shaw S., d'Uscio L.V., Moreau P., and Luscher T.F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238 (1997) 861-865
17. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
18. Haynes W.G., and Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16 (1998) 1081-1098
19. Barton M., Haudenschild C.C., d'Uscio L.V., Shaw S., Munter K., and Luscher T.F. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 95 (1998) 14367-14372
20. Hafizi S., Allen S.P., Goodwin A.T., Chester A.H., and Yacoub M.H. Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis 146 (1999) 351-359
21. Franco Mdo C., Akamine E.H., Di Marco G.S., Casarini D.E., Fortes Z.B., Tostes R.C., et al. NADPH oxidase and enhanced superoxide generation in intrauterine undernourished rats: involvement of the renin-angiotensin system. Cardiovasc Res 59 (2003) 767-775
22. Li L., Fink G.D., Watts S.W., Northcott C.A., Galligan J.J., Pagano P.J., et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107 (2003) 1053-1058
23. Barton M., Carmona R., Ortmann J., Krieger J.E., and Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 35 (2003) 826-837
24. Barton M., Carmona R., Morawietz H., d'Uscio L.V., Goettsch W., Hillen H., et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 35 (2000) 329-336
25. Ferri C., Bellini C., Desideri G., Baldoncini R., Properzi G., Santucci A., et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 105 Suppl 2 (1997) 38-40
26. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004) 1752-1761
27. Petro A.E., Cotter J., Cooper D.A., Peters J.C., Surwit S.J., and Surwit R.S. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53 (2004) 454-457
28. Stein E.A., and Myers G.L. Lipids, lipoproteins, and apolipoproteins. In: Brutis C.A., and Ashwood E.R. (Eds). Tietz textbook of clinical chemistry (1994), W.B. Saunders, Philadelphia, PA 1002-1093
29. Traupe T., Lang M., Goettsch W., Munter K., Morawietz H., Vetter W., et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 20 (2002) 2239-2245
30. Kretz M., Mundy A.L., Widmer C.C., and Barton M. Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice. J Cardiovasc Pharmacol 48 (2006) 1-4
31. Widmer C.C., Mundy A.L., Kretz M., and Barton M. Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries. Exp Biol Med (Maywood) 231 (2006) 777-781
32. Udenfriend S., Clark C.T., Axelrod J., and Brodie B.B. Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem 208 (1954) 731-739
33. Mundy A.L., Widmer C.C., Kretz M., Haas E., and Barton M. Leptin deficiency unmasks an indirect vasodilator effect of hydroxyl radical on the vascular response to endothelin-1. Hypertension 46 (2005) 844 [abstract]
34. Barreto J.C., Smith G.S., Strobel N.H., McQuillin P.A., and Miller T.A. Terephthalic acid: a dosimeter for the detection of hydroxyl radicals in vitro. Life Sci 56 (1995) L89-L96
35. Saran M., and Summer K.H. Assaying for hydroxyl radicals: hydroxylated terephthalate is a superior fluorescence marker than hydroxylated benzoate. Free Radic Res 31 (1999) 429-436
36. Emmanuele L., Ortmann J., Doerflinger T., Traupe T., and Barton M. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 302 (2003) 67-72
37. Buschbeck M., and Ullrich A. The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem 280 (2005) 2659-2667
38. Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 71 (1992) 169-180
39. Nielsen S., Halliwill J.R., Joyner M.J., and Jensen M.D. Vascular response to angiotensin II in upper body obesity. Hypertension 44 (2004) 435-441
40. Zhang C., Knudson J.D., Setty S., Araiza A., Dincer U.D., Kuo L., et al. Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors. Am J Physiol Heart Circ Physiol 288 (2005) H2154-H2162
41. Zhou Y., Chen Y., Dirksen W.P., Morris M., and Periasamy M. AT1b receptor predominantly mediates contractions in major mouse blood vessels. Circ Res 93 (2003) 1089-1094
42. Vaziri N.D., Xu Z.G., Shahkarami A., Huang K.T., Rodriguez-Iturbe B., and Natarajan R. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int 68 (2005) 2787-2793
43. Luscher T.F., and Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102 (2000) 2434-2440
44. Peterson L.R., Waggoner A.D., Schechtman K.B., Meyer T., Gropler R.J., Barzilai B., et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 43 (2004) 1399-1404
45. Chen S.X., and Schopfer P. Hydroxyl-radical production in physiological reactions. A novel function of peroxidase. Eur J Biochem 260 (1999) 726-735
46. Li J., Li W., Liu W., Altura B.T., and Altura B.M. Mechanisms of hydroxyl radical-induced contraction of rat aorta. Eur J Pharmacol 499 (2004) 171-178
47. Roberts C.K., Barnard R.J., Sindhu R.K., Jurczak M., Ehdaie A., and Vaziri N.D. A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression. J Appl Physiol 98 (2005) 203-210
48. Noronha B.T., Li J.M., Wheatcroft S.B., Shah A.M., and Kearney M.T. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 54 (2005) 1082-1089
49. Zhou Y., Varadharaj S., Zhao X., Parinandi N., Flavahan N.A., and Zweier J.L. Acetylcholine causes endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol 289 (2005) H1027-H1032
50. Weghuber D, Zaknun D, Nasel C, Willforth-Ehringer A, Muller T, Boriss-Riedl M, et al. Early cerebrovascular disease in a 2-year-old with extreme obesity and complete metabolic syndrome due to feeding of excessively high amounts of energy. Eur J Pediatr in press, doi:10.1007/s00431-006-0204-2.
51. McGill Jr. H.C., McMahan C.A., Herderick E.E., Zieske A.W., Malcom G.T., Tracy R.E., et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105 (2002) 2712-2718